Solvonis Therapeutics(GB:SVNS)
GBXÂ 0.09+0.00 (+5.88%)
GB:SVNS
Solvonis Therapeutics financials statements
GBXÂ 0.09
At close:+0.00 (+5.88%)
Want to see GB:SVNS full AI Analyst Report?
Solvonis Therapeutics (SVNS) Ratios
14 Followers
Solvonis Therapeutics Ratios
GB:SVNS's free cash flow for Q4 2025 was £-2.26M. For the 2025 fiscal year, GB:SVNS's free cash flow was increased by £0.00 and operating cash flow was £-2.26M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 4.00 | 6.85 | 0.81 | 5.88 | 0.32 |
| Quick Ratio | 4.00 | 6.85 | 0.68 | 5.37 | 0.32 |
| Cash Ratio | 3.58 | 6.36 | 0.40 | 4.47 | 0.26 |
| Solvency Ratio | -4.12 | -13.36 | -7.21 | -6.73 | -0.39 |
| Operating Cash Flow Ratio | -6.82 | -9.50 | -3.21 | -6.43 | -0.11 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | -0.27 |
| Net Current Asset Value | £ 524.00K | £ 696.00K | £ -94.00K | £ 1.77M | £ -1.58M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.01 | 0.00 | 0.01 | 0.00 | 0.30 |
| Debt-to-Equity Ratio | 0.01 | 0.00 | 0.02 | 0.00 | 1.17 |
| Debt-to-Capital Ratio | 0.01 | 0.00 | 0.02 | 0.00 | 0.54 |
| Long-Term Debt-to-Capital Ratio | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.23 | 1.04 | 1.20 | 1.08 | 3.85 |
| Debt Service Coverage Ratio | 0.00 | -21.61 | -979.33 | -647.00 | -0.94 |
| Interest Coverage Ratio | 0.00 | -21.61 | -1039.00 | -677.00 | -105.63 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 |
| Interest Debt Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Net Debt to EBITDA | 0.29 | 0.55 | 0.04 | 0.63 | -0.39 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | -22.83% | -9.41% | 25.11% |
| EBIT Margin | 0.00% | 0.00% | -531.01% | -498.34% | -431.96% |
| EBITDA Margin | 0.00% | 0.00% | -500.51% | -477.49% | -410.96% |
| Operating Profit Margin | 0.00% | 0.00% | -531.01% | -499.63% | -385.84% |
| Pretax Profit Margin | 0.00% | 0.00% | -531.52% | -499.08% | -435.62% |
| Net Profit Margin | 0.00% | 0.00% | -531.52% | -499.08% | -435.62% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | -531.52% | -499.08% | -435.62% |
| Net Income Per EBT | 100.00% | 109.88% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 165.08% | 104.63% | 100.10% | 99.89% | 112.90% |
| Return on Assets (ROA) | -75.68% | -49.64% | -128.18% | -54.77% | -30.48% |
| Return on Equity (ROE) | -92.72% | -51.56% | -154.00% | -59.40% | -117.49% |
| Return on Capital Employed (ROCE) | -48.94% | -44.84% | -152.20% | -59.23% | -104.06% |
| Return on Invested Capital (ROIC) | -48.94% | -44.84% | -151.31% | -59.18% | -47.96% |
| Return on Tangible Assets | -299.27% | -142.60% | -852.46% | -94.22% | -89.83% |
| Earnings Yield | -38.06% | -67.05% | -521.45% | -18.79% | -4.14% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 8.27 | 12.60 | 5.09 |
| Payables Turnover | 0.00 | 0.00 | 2.81 | 3.21 | 0.20 |
| Inventory Turnover | 0.00 | 0.00 | 8.75 | 3.17 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 15.05 | 0.77 | 0.71 |
| Asset Turnover | 0.00 | 0.00 | 0.24 | 0.11 | 0.07 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.68 | 5.11 | -0.17 |
| Cash Conversion Cycle | 0.00 | 0.00 | -44.24 | 30.19 | -1800.07 |
| Days of Sales Outstanding | 0.00 | 0.00 | 44.15 | 28.96 | 71.67 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 41.74 | 115.10 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 130.12 | 113.87 | 1871.74 |
| Operating Cycle | 0.00 | 0.00 | 85.89 | 144.06 | 71.67 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.00 | -0.00 | -0.01 | -0.02 | -0.00 |
| Free Cash Flow Per Share | -0.00 | -0.00 | -0.01 | -0.03 | -0.00 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | -282.50 | -5.34 | -3.29 | -254.00 |
| Capital Expenditure Coverage Ratio | 0.00 | -282.50 | -5.34 | -3.29 | -254.00 |
| Operating Cash Flow Coverage Ratio | -43.64 | 0.00 | -36.41 | -107.27 | -0.27 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | -2.11 | -4.35 | -1.16 |
| Free Cash Flow Yield | -21.70% | -47.82% | -245.68% | -21.38% | -1.11% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -2.58 | -1.71 | -0.19 | -5.32 | -24.15 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 1.02 | 26.57 | 105.19 |
| Price-to-Book (P/B) Ratio | 2.44 | 0.77 | 0.30 | 3.16 | 28.37 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -4.61 | -2.09 | -0.41 | -4.68 | -90.34 |
| Price-to-Operating Cash Flow Ratio | -4.61 | -2.10 | -0.48 | -6.10 | -90.70 |
| Price-to-Earnings Growth (PEG) Ratio | 0.00 | 0.02 | -0.01 | -0.03 | -0.10 |
| Enterprise Value Multiple | -2.34 | -1.17 | -0.16 | -4.94 | -25.99 |
| Enterprise Value | 13.44M | 1.61M | 477.33K | 12.78M | 23.39M |
| EV to EBITDA | -2.34 | -1.17 | -0.16 | -4.94 | -25.99 |
| EV to Sales | 0.00 | 0.00 | 0.81 | 23.58 | 106.80 |
| EV to Free Cash Flow | -4.10 | -1.42 | -0.32 | -4.15 | -91.72 |
| EV to Operating Cash Flow | -4.10 | -1.43 | -0.39 | -5.42 | -92.08 |
| Tangible Book Value Per Share | 0.00 | 0.00 | -0.00 | 0.02 | -0.01 |
| Shareholders’ Equity Per Share | 0.00 | 0.00 | 0.02 | 0.04 | 0.01 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 |
| Net Income Per Share | -0.00 | -0.00 | -0.03 | -0.03 | -0.01 |
| Tax Burden | 1.00 | 1.10 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.05 | 1.00 | 1.00 | 1.01 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 1.15 | 4.92 | 7.05 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.63 | 1.58 | 0.00 |
| Income Quality | 0.57 | 0.71 | 0.40 | 0.87 | 0.27 |
Currency in GBP
